A recent study reported in the Renal and Urology News show that continuous ADT treatment has a better survival rate than the present procedure of intermittent ADT treatment.
Hormonal treatment (ADT treatment) are presently prescribed in monthly or three monthly sessions for one to three years. The main rational being the body will development resistance to the hormones induced. There is also a re-challenge stage if the PSA starts to rise again.
The new17 years old study shows a better survival rate if ADT treatments are continuous until the point of resistance by the body. It is obviously not a case of one solution for all cases.
Extract from the report.
Intermittent androgen deprivation therapy (ADT) has some quality-of-life (QOL) benefits for men with metastatic prostate cancer (PCa), but overall survival times are inferior to those seen with continuous ADT, according to the findings of a 17-year study (SWOG9346) presented at the American Society for Clinical Oncology 2012 annual meeting.
“Some doctors recommend intermittent hormonal therapy to men with metastatic prostate cancer, believing it will reduce their risk of side effects without compromising their outcome, but these findings demonstrate a downside to this approach for certain men,” said lead researcher Maha Hussain, MD, Professor of Medicine and Urology at the University of Michigan Comprehensive Cancer Center in Ann Arbor.
“The findings clearly demonstrate that intermittent hormonal therapy is not as effective for all patients with metastatic prostate cancer. These findings are likely practice changing for many doctors in the U.S. and abroad who routinely use intermittent therapy; specifically, physicians must counsel interested patients regarding the potential negative impact on survival with intermittent therapy.”
Read more from the link below:
http://www.renalandurologynews.com/survival-better-with-continuous-adt/article/244075/#
Allen Lai
No comments:
Post a Comment